What's in a Word? Falsified/Counterfeit/Fake Medicines - The Definitions Debate

M. Isles
{"title":"What's in a Word? Falsified/Counterfeit/Fake Medicines - The Definitions Debate","authors":"M. Isles","doi":"10.5301/MAAPOC.0000008","DOIUrl":null,"url":null,"abstract":"There is a rising tide of criminal activity to manufacture and distribute falsified, counterfeit, or fake medicines. The exact size of this problem is unknown but estimates vary from US$75 billion to US$200 billion per year, and evidence clearly demonstrates it is on the increase. Depending on the world region, infiltration into the legitimate supply chain versus the illegitimate (e.g., the internet) varies greatly. However, what is certain is that the direction of travel by regulatory agents is to develop supply chains that allow access to medicines via the World Wide Web. Within this context, there has been a long-running debate about how to correctly describe the various forms of medicines that are fraudulently or otherwise manufactured and distributed. This article attempts to describe the evolution of the definitions and recommends that a consensus be formed to describe such medicines that reach the public: • Falsified medicine: This being the term used and defined in the Falsified Medicines Directive and which is primarily concerned with public health. • Counterfeit medicine: This is closely associated and legally defined within intellectual property legislation and concentrates on trademark protection. • Fake medicine: This is the term that best serves to communicate with the public to raise awareness about the phenomenon.","PeriodicalId":74158,"journal":{"name":"Medicine access @ point of care","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5301/MAAPOC.0000008","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine access @ point of care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5301/MAAPOC.0000008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

There is a rising tide of criminal activity to manufacture and distribute falsified, counterfeit, or fake medicines. The exact size of this problem is unknown but estimates vary from US$75 billion to US$200 billion per year, and evidence clearly demonstrates it is on the increase. Depending on the world region, infiltration into the legitimate supply chain versus the illegitimate (e.g., the internet) varies greatly. However, what is certain is that the direction of travel by regulatory agents is to develop supply chains that allow access to medicines via the World Wide Web. Within this context, there has been a long-running debate about how to correctly describe the various forms of medicines that are fraudulently or otherwise manufactured and distributed. This article attempts to describe the evolution of the definitions and recommends that a consensus be formed to describe such medicines that reach the public: • Falsified medicine: This being the term used and defined in the Falsified Medicines Directive and which is primarily concerned with public health. • Counterfeit medicine: This is closely associated and legally defined within intellectual property legislation and concentrates on trademark protection. • Fake medicine: This is the term that best serves to communicate with the public to raise awareness about the phenomenon.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
单词里有什么?伪造/假冒/假药-定义辩论
制造和分销伪造、假冒或假药的犯罪活动呈上升趋势。这一问题的确切规模尚不清楚,但估计每年的规模从750亿美元到2000亿美元不等,而且有证据清楚地表明,这一问题正在增加。根据世界地区的不同,对合法供应链和非法供应链(如互联网)的渗透差别很大。然而,可以肯定的是,监管机构的方向是发展供应链,允许通过万维网获得药品。在此背景下,关于如何正确描述欺诈或以其他方式制造和销售的各种形式的药物一直存在长期争论。本文试图描述定义的演变,并建议形成共识,以描述公众接触到的此类药物:•伪造药物:这是在伪造药品指令中使用和定义的术语,主要与公共卫生有关。•假药:这是与知识产权立法密切相关并在法律上定义的,主要集中在商标保护上。•假药:这个词最能与公众沟通,提高人们对这一现象的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
15 weeks
期刊最新文献
A structural equation modeling of supply chain strategies for artemisinin-based combination therapies in Uganda. Antibiotic consumption at community pharmacies: A multicenter repeated prevalence surveillance using WHO methodology. Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria. Point-of-care high-sensitivity assay on PATHFAST as the backup in the emergency room. Medicine quality in high-income countries: The obstacles to comparative prevalence studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1